ETERNAL's third newsletter features two important positioning papers from the ETERNAL stable: a concept paper laying out the key-drivers and a possible regulatory roadmap for “compliant-by-design” pharmaceutical strategies on the one hand, and a review of current and future EMA regulation covering the environmental risk assessment of pharmaceuticals complete with areas where these could be strengthened, improved and gaps filled. You can also read about some of our plans for conferences and workshops in the frst half of 2024.

We look forward into the year ahead with a sense of growing excitement as the ETERNAL project’s collaborative research and case study strands gather pace. With several parts of the project’s work programme starting to deliver early results and work progressing strongly across the board, we are looking forward to sharing some of the early highlights and our latest thinking at two notable gatherings of industrialists and researchers from the pharmaceutical and specialty chemicals sectors respectively in the first half of 2024.